Brittany N Cadiz, NP
Nurse Practitioner · Anaheim
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 2
- Since medical school
- 5 years
- Graduated 2021
Offices
2 locations · Mental Health and Nursing PC · 10 clinicians in this group
Hospitals listed: West Anaheim Medical Center. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Brittany N Cadiz’s office at (714) 361-0898 to ask if they take your plan before you enroll.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- West Anaheim Medical CenterAnaheim, CAAcute Care Hospital · Proprietary · Has an emergency departmentPart of Prime Healthcare Services, which runs 45 hospitals in 14 statesPatients rate it 2 of 5 · 57% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.064, Oct 2024 – Sep 2025
See every measure and the patient survey for West Anaheim Medical Center
Behind the star rating — Deaths: 0 better, 6 the same, 0 worse of 6 measures. Safety: 1 better, 5 the same, 0 worse of 6 measures. Readmissions: 0 better, 1 the same, 4 worse of 5 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.064 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.93 (0 to 1.96) · 557 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.79 (0.42 to 1.17) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 190.47 (138.32 to 242.62) · 36 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 6.5 · 60 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.9 · 67 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.5 · 121 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13.8 · 491 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 16 · 43 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 4.3 · 1,918 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.17 (0 to 0.38) · 3,521 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.23 (0.03 to 0.44) · 3,582 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.23 (0.86 to 5.6) · 351 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.14 (0.48 to 3.8) · 313 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.71 (0.2 to 3.22) · 83 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.13 (0 to 0.73) · 2,948 cases | No different | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.723 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.319 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.479 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.6 · 133 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.7 · 229 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.4 · 85 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -3.3 · 141 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 49.6 · 532 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19.5 · 656 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.5 · 107 cases | None | Jul 2023 – Jun 2025 |
What patients said (454 patients answered, 15% of those asked)
| Cleanliness | 3 |
| Nurse communication | 1 |
| Doctor communication | 1 |
| Communication about medicines | 1 |
| Discharge information | 2 |
| Overall hospital rating | 3 |
| Quietness | 1 |
| Recommend hospital | 2 |
| Room was "always" clean | 69% |
| Nurses "always" communicated well | 67% |
| Doctors "always" communicated well | 68% |
| Staff "always" explained | 50% |
| Yes, staff "did" give patients this information | 79% |
| Yes, staff "did" give patients information about help after discharge | 76% |
| Doctors "always" explained things so they could understand | 64% |
| Doctors "always" listened carefully | 65% |
| Doctors "always" treated them with courtesy and respect | 74% |
| Patients who gave a rating of "9" or "10" (high) | 59% |
| Staff "always" explained new medications | 62% |
| Nurses "always" explained things so they could understand | 62% |
| Nurses "always" listened carefully | 62% |
| Nurses "always" treated them with courtesy and respect | 76% |
| "Always" quiet at night | 38% |
| "YES", patients would definitely recommend the hospital | 57% |
| Staff "always" explained possible side effects | 39% |
| Yes, staff "did" give patients information about possible symptoms | 82% |
Original Medicare doctor bills
$77,392
Medicare paid this office $77,392 for 77 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Psychotherapy with evaluation and management visit, 30 minutes | 53 | $31,989 | $45 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 53 | $25,910 | $34 |
| Return visit (30+ min) | 12 | $6,955 | $67 |
| Psychotherapy with evaluation and management visit, 30 minutes | 12 | $4,743 | $44 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 30 | $3,185 | $91 |
See all 6 services
| Psychotherapy with evaluation and management visit, 30 minutes | 53 | $31,989 | $45 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 53 | $25,910 | $34 |
| Return visit (30+ min) | 12 | $6,955 | $67 |
| Psychotherapy with evaluation and management visit, 30 minutes | 12 | $4,743 | $44 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 30 | $3,185 | $91 |
| Hospital discharge day management, 30 minutes or less | 38 | $2,490 | $57 |
Who their Medicare patients are
77 Original Medicare patients in 2024. Average age 63 · Under 65 44% · Women 43% · Health risk score 2.13. Above the middle of the specialty; the typical nurse practitioner clinician is at 1.42.
Conditions among them: High blood pressure 75% · Depression 75% · Diabetes 40% · COPD 40% · Dementia 40% · Chronic kidney disease 32% · Heart failure 27% · Coronary heart disease 26% · Atrial fibrillation 14%.
The office billed $234,365, Medicare allowed $97,765 and paid $77,392; for 1,785 services of 12 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 77 | 1,785 | 63 | 2.13 | $234,365 | $77,392 |
| 2023 | 69 | 1,722 | 63 | 2.35 | $217,985 | $72,050 |
| 2022 | 63 | 1,432 | 66 | 2.58 | $184,075 | $57,562 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 4 services
| Psychotherapy with evaluation and management visit, 30 minutes | 52 | $29,067 | $43 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 53 | $28,623 | $35 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 42 | $4,764 | $90 |
| Hospital discharge day management, 30 minutes or less | 33 | $2,497 | $58 |
2022: 5 services
| Psychotherapy with evaluation and management visit, 30 minutes | 47 | $27,109 | $45 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 47 | $17,136 | $28 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 16 | $6,002 | $51 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 30 | $3,570 | $96 |
| Hospital discharge day management, 30 minutes or less | 21 | $1,299 | $52 |
Medicaid work
$152,227 in 2024
Medicaid paid $152,227 for 2,084 billed services this clinician did in 2024, up to 104 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 906 | $89,291 |
| Psychotherapy, 30 minutes with patient when performed with an evaluation and management service (List separately in addition to the code for primary procedure) | 1,064 | $53,171 |
| New patient visit (45+ min) | 44 | $5,306 |
| Short return visit (20+ min) | 70 | $4,459 |
| 2024 | 2,084 | 4 | 104 | $152,227 |
| 2023 | 1,406 | 5 | 97 | $65,661 |
See the largest Medicaid services in earlier years
2023
| Short return visit (20+ min) | 456 | $27,892 |
| Psychotherapy, 30 minutes with patient when performed with an evaluation and management service (List separately in addition to the code for primary procedure) | 801 | $25,388 |
| Return visit (30+ min) | 98 | $6,511 |
| New patient visit (45+ min) | 38 | $4,245 |
| Psychiatric diagnostic evaluation with medical services | 13 | $1,625 |
Drugs they prescribed that Part D paid
$37,950
Pharmacies billed $37,950 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 345) in 2024. At or below the middle of the specialty; the typical nurse practitioner clinician is at 0%.
314 generic and 31 brand-name prescriptions · $37,950 in drug cost · 35 antipsychotic prescriptions to people over 65.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Lybalvi | 13 | $20,025 | $1,540 |
| Vyvanse | 12 | $5,308 | $442 |
| Bupropion Xl | 22 | $721 | $33 |
| Quetiapine | 35 | $475 | $14 |
| Divalproex | 12 | $244 | $20 |
See all 16 drugs
| Lybalvi | 13 | $20,025 | $1,540 |
| Vyvanse | 12 | $5,308 | $442 |
| Bupropion Xl | 22 | $721 | $33 |
| Quetiapine | 35 | $475 | $14 |
| Divalproex | 12 | $244 | $20 |
| Olanzapine | 16 | $192 | $12 |
| Alprazolam | 21 | $125 | $6 |
| Hydroxyzine Pamoate | 15 | $105 | $7 |
| Risperidone | 21 | $100 | $5 |
| Clonazepam | 18 | $98 | $5 |
| Paroxetine | 20 | $63 | $3 |
| Lorazepam | 11 | $58 | $5 |
| Escitalopram | 25 | $45 | $2 |
| Buspirone | 11 | $43 | $4 |
| Sertraline | 14 | $38 | $3 |
| Diazepam | 11 | $19 | $2 |
Year by year
| 2024 | 345 | 24 | 0% (0) | 9% | $37,950 |
| 2023 | 242 | 14 | 0% (0) | 8% | $20,871 |
| 2022 | 15 | None | 0% (0) | None | $1,369 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 13 drugs
| Vyvanse | 12 | $4,824 | $402 |
| Bupropion Xl | 12 | $709 | $59 |
| Quetiapine | 23 | $373 | $16 |
| Olanzapine | 14 | $330 | $24 |
| Alprazolam | 22 | $182 | $8 |
| Clonazepam | 18 | $173 | $10 |
| Risperidone | 20 | $144 | $7 |
| Paroxetine | 13 | $113 | $9 |
| Bupropion Hcl Sr | 12 | $105 | $9 |
| Fluoxetine | 16 | $72 | $5 |
| Hydroxyzine | 11 | $65 | $6 |
| Diazepam | 15 | $55 | $4 |
| Escitalopram | 13 | $43 | $3 |
Money from drug and device companies
$682 in 2025
| 2025 | 12 | 30 | None | $682 |
| 2024 | 14 | 85 | None | $2,030 |
| 2023 | 13 | 125 | None | $3,042 |
| 2022 | 11 | 21 | None | $567 |
| 2021 | 1 | 1 | None | $125 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Abbvie | Vraylar | $117 | 6 payments
|
| Otsuka America Pharmaceutical | Rexulti | $93 | 3 payments
|
| Vanda Pharmaceuticals | Fanapt | $88 | 3 payments
|
| E.R. Squibb & Sons L.L.C. | Cobenfy | $84 | 3 payments
|
| Neurocrine BioSciences | Ingrezza | $81 | 3 payments
|
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Caplyta | $55 | 3 payments
|
See all 30 published payments
| Vanda Pharmaceuticals | Meals · 2025-12-18 | Fanapt | $23 |
| Abbvie | Meals · 2025-12-12 | Vraylar | $14 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-10-30 | Cobenfy | $27 |
| Biogen | Meals · 2025-10-28 | Zurzuvae | $27 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-10-15 | Caplyta | $14 |
| Abbvie | Meals · 2025-10-03 | Vraylar | $20 |
| Supernus Pharmaceuticals | Meals · 2025-09-15 | Qelbree | $14 |
| Abbvie | Meals · 2025-08-29 | Vraylar | $21 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-08-29 | Caplyta | $20 |
| Neurocrine BioSciences | Meals · 2025-08-29 | Ingrezza | $29 |
| GlaxoSmithKline | Meals · 2025-08-25 | Nucala | $31 |
| Otsuka America Pharmaceutical | Meals · 2025-08-21 | Rexulti | $33 |
| Corium | Meals · 2025-08-19 | Azstarys | $17 |
| Otsuka America Pharmaceutical | Meals · 2025-08-08 | Abilify Maintena | $32 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-08-05 | Caplyta | $21 |
| Corium | Meals · 2025-07-22 | Azstarys | $3 |
| Abbvie | Meals · 2025-07-18 | Vraylar | $21 |
| Neurocrine BioSciences | Meals · 2025-07-18 | Ingrezza | $29 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-06-27 | Cobenfy | $31 |
| Corium | Meals · 2025-06-24 | Azstarys | $10 |
| Vanda Pharmaceuticals | Meals · 2025-06-19 | Fanapt | $31 |
| Abbvie | Meals · 2025-06-13 | Vraylar | $26 |
| Vanda Pharmaceuticals | Meals · 2025-05-23 | Fanapt | $34 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-05-15 | Cobenfy | $25 |
| Neurocrine BioSciences | Meals · 2025-04-26 | Ingrezza | $23 |
| Otsuka America Pharmaceutical | Meals · 2025-04-24 | Rexulti | $29 |
| Abbvie | Meals · 2025-03-22 | Vraylar | $15 |
| Supernus Pharmaceuticals | Meals · 2025-02-27 | Qelbree | $14 |
| Alkermes | Meals · 2025-02-20 | Aristada | $15 |
| Janssen Pharmaceuticals | Meals · 2025-02-05 | Spravato | $33 |
See earlier years (2024, 2023, 2022, 2021)
2024: $2,030
| Abbvie | Vraylar | $542 | 22 payments
|
| Supernus Pharmaceuticals | Qelbree | $516 | 15 payments
|
| Janssen Pharmaceuticals | Spravato | $213 | 9 payments
|
| Almatica Pharma | Loreev Xr | $141 | 5 payments
|
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Caplyta | $133 | 14 payments
|
| Otsuka America Pharmaceutical | Rexulti | $101 | 4 payments
|
| Vanda Pharmaceuticals | Fanapt | $79 | 3 payments
|
| Alkermes | Aristada | $70 | 3 payments
|
| Corium | Azstarys | $58 | 2 payments
|
| Teva Pharmaceuticals USA | Uzedy | $56 | 2 payments
|
| Biogen | None | $45 | 2 payments
|
| Lundbeck | Rexulti | $36 | 2 payments
|
| Neurocrine Biosciences | Ingrezza | $23 | 1 payment
|
| Tris Pharma | Dyanavel Xr | $17 | 1 payment
|
2023: $3,042
| Abbvie | Vraylar | $586 | 22 payments
|
| Alkermes | Aristada | $560 | 19 payments
|
| Indivior | Perseris | $332 | 14 payments
|
| Iti | Caplyta | $316 | 20 payments
|
| Almatica Pharma | Sertraline Hcl | $257 | 10 payments
|
| Janssen Pharmaceuticals | Invega Sustenna | $254 | 8 payments
|
| Neurocrine Biosciences | Ingrezza | $152 | 5 payments
|
| Otsuka America Pharmaceutical | Abilify Maintena | $145 | 7 payments
|
| Teva Pharmaceuticals USA | Uzedy | $140 | 7 payments
|
| Lundbeck | Rexulti | $104 | 4 payments
|
| Corium | Azstarys | $95 | 5 payments
|
| Axsome Therapeutics | Auvelity | $67 | 2 payments
|
| Neuronetics | Neurostar Tms Therapy System | $33 | 2 payments
|
2022: $567
| Almatica Pharma | Citalopram | $90 | 3 payments
|
| Janssen Pharmaceuticals | Invega Sustenna | $86 | 2 payments
|
| Indivior | Perseris | $83 | 3 payments
|
| Neurocrine Biosciences | Ingrezza | $73 | 2 payments
|
| Alkermes | Aristada | $72 | 3 payments
|
| Otsuka America Pharmaceutical | Abilify Maintena | $49 | 2 payments
|
| Teva Pharmaceuticals USA | Austedo | $48 | 2 payments
|
| Abbvie | Vraylar | $25 | 1 payment
|
| Takeda Pharmaceuticals U.S.A. | Trintellix | $23 | 1 payment
|
| Iti | Caplyta | $12 | 1 payment
|
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Caplyta | $6 | 1 payment
|
2021: $125
| Neurocrine Biosciences | Ingrezza | $125 | 1 payment
|
Professional record
- NPI
- 1790398295
- Licence
- CA 95017843, CA 95127251
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 363LP0808X (363LP0808X); Federal specialty code 163W00000X (163W00000X); Federal specialty code 163WP0809X (163WP0809X)
- Mailing address
- 4276 Katella Ave Ste 220, Los Alamitos, CA, 90720
- NPI first listed
- 2020-08-25
- NPI last updated
- 2023-03-13
- NPI record certified
- 2023-03-13
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 14659 Olive View Dr, Sylmar, CA, 91342